Sign In
Buy CDXS
$2.72
+0.0300 (+1.12%)
At Close: Jun 03, 2026
Codexis to Participate in Upcoming Virtual Healthcare Conferences
04:05pm, Tuesday, 07'th Sep 2021
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management w
After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright
10:53am, Tuesday, 10'th Aug 2021
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript
03:18pm, Saturday, 07'th Aug 2021
Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
09:17pm, Thursday, 05'th Aug 2021
Codexis (CDXS) delivered earnings and revenue surprises of 58.82% and 41.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif. and KALAMAZOO, Mich., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, I
ARK Investment Leans Into Biotech and Telecom Holdings
03:39pm, Monday, 12'th Jul 2021
Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.
Codexis Earns Milestone Payment from GlaxoSmithKline
04:05pm, Wednesday, 07'th Jul 2021
REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant
Strength Seen in Codexis (CDXS): Can Its 12.6% Jump Turn into More Strength?
01:31am, Monday, 21'st Jun 2021
Codexis (CDXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product
07:13am, Friday, 18'th Jun 2021
Codexis Inc (NASDAQ: CDXS) raised its guidance for 2021 following the receipt of a binding purchase order for up to $13.9 million of a proprietary high-performance enzyme product from an undisclose
Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product
04:44pm, Thursday, 17'th Jun 2021
REDWOOD CITY, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021,
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic co
Codexis to Participate in Upcoming Virtual Healthcare Conferences
04:05pm, Tuesday, 25'th May 2021
REDWOOD CITY, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual in
Codexis to Participate in Upcoming Virtual Healthcare Conferences
04:05pm, Monday, 17'th May 2021
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual inv
Codexis, Inc. (CDXS) CEO John Nicols on Q1 2021 Results - Earnings Call Transcript
04:46am, Sunday, 09'th May 2021
Codexis, Inc. (CDXS) CEO John Nicols on Q1 2021 Results - Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates
07:32pm, Thursday, 06'th May 2021
Codexis (CDXS) delivered earnings and revenue surprises of 30.00% and 21.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
